Zelira’s Revolutionary Painkiller Outperforms Big Pharma Giant, Sets Cannabis Medicine on Fire!

Zelira Therapeutics (ZLD ZLDAF), a prominent player in cannabinoid medicine research, has achieved a remarkable feat by showcasing the superiority of its proprietary drug, ZLT-L-007, over Pfizer’s popular drug, Lyrica, in treating diabetic nerve pain. The company has just completed a well designed and executed multi-arm clinical trial where  its new drug  ZLT-L-007 was pitted against Lyrica. Lyrica’s is known for raking in close to $5 billion in annual sales. The objective of the study was to evaluate ZLT-L-007's ability to rival Lyrica's analgesic properties.

The results were striking, revealing a significant reduction in NRS pain scores for patients treated with ZLT-L-007, indicating a clear decrease in symptom severity. Notably, ZLT-L-007 demonstrated outstanding safety and tolerability, surpassing Lyrica's pain management capabilities in certain instances. Importantly, the trial met its primary safety threshold with no recorded Serious Adverse Events (SAE).

Zelira's chairman, Osagie Imasogie, expressed confidence and optimism in the findings, highlighting the potential for ZLT-L-007 to progress into formal FDA clinical trials. This success aligns with Zelira's commitment to developing safe and effective cannabinoid-derived drugs catering to various therapeutic areas.

Zelira Therapeutics CEO and managing director, Dr. Oludare Odumosu, attributed this accomplishment to the company's rigorous scientific approach and data-driven development of patient-centered cannabinoid-based drugs. ZLT-L-007's triumph can be attributed, in part, to Zelira's innovative Zyraydi technology, enabling the production of easy-to-swallow pharmaceutical-grade capsules for efficient pain management. As Zelira continues on its promising trajectory, further insights from the full study are expected to be released during the fiscal year 2023-2024. These results underscore Zelira's successful “Launch, Learn and Develop” strategy, paving the way for future FDA clinical trials and potential regulatory approval of ZLT-L-007. The trial outcomes not only mark a significant achievement for Zelira but also represent a noteworthy milestone for the cannabis-based pharmaceutical industry, propelling it closer to mainstream recognition and acceptance.